Inventor · disambiguated record
Juergen Scheele
Also filed as: SCHEELE JUERGEN
7 granted patents·3 pending applications·40 citations·filing 2011–2022
83Inventor score
Top patents by PatentIndex Score
10 records- 0190US9688760B2Anti-leukocyte adhesion for the mitigation of potential adverse events caused by CD3-specific binding domainsAMGEN RES MUNICH GMBH·Filed 2014·Granted Jun 27, 2017·17 cites·10 claims
- 0289US11084876B2Anti-leukocyte adhesion for the mitigation of potential adverse events caused by CD3-specific binding domainsAMGEN RES MUNICH GMBH·Filed 2017·Granted Aug 10, 2021·4 cites·14 claims
- 0384US10696744B2Means and methods for treating DLBCLAMGEN RES MUNICH GMBH·Filed 2015·Granted Jun 30, 2020·3 cites·13 claims
- 0481US9192665B2Means and methods for treating DLBCLZUGMAIER GERHARD·Filed 2011·Granted Nov 24, 2015·7 cites·19 claims
- 0579US10130638B2Prevention of adverse effects caused by CD3 specific binding domainsZUGMAIER GERHARD·Filed 2011·Granted Nov 20, 2018·5 cites·12 claims
- 0678US9486475B2PPS for the prevention of potential adverse effects caused by CD3 specific binding domainsAMGEN RES MUNICH GMBH·Filed 2014·Granted Nov 8, 2016·4 cites·14 claims
- 0758US2023137669A1Determining drug combinations, synergistic drug combination and use thereof in pancreatic cancer treatmentINNOPLEXUS AG·Filed 2022·Application pending·0 cites
- 0855US2022016116A1Determining drug combinations, synergistic drug combination and use thereof in pancreatic cancer treatmentINNOPLEXUS AG·Filed 2021·Application pending·0 cites
- 0953US11633408B2Prevention of adverse effects caused by CD3 specific binding domainsAMGEN RES MUNICH GMBH·Filed 2018·Granted Apr 25, 2023·0 cites·16 claims
- 1047US2022020465A1Method and system for evaluating potential drug compositions for target diseaseINNOPLEXUS AG·Filed 2021·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Juergen Scheele files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →